Cargando…
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
BACKGROUND: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. CASE: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the combination of pembrolizumab, a PD-1...
Autores principales: | McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Max Philipp Hartwich, Tobias, Santin, Alessandro D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265468/ https://www.ncbi.nlm.nih.gov/pubmed/37325296 http://dx.doi.org/10.1016/j.gore.2023.101218 |
Ejemplares similares
-
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023) -
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
por: Bellone, Stefania, et al.
Publicado: (2023) -
Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
por: Fellouah, Massine, et al.
Publicado: (2023) -
Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
por: Heisler, Elise, et al.
Publicado: (2023) -
Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report
por: Lehmann, M., et al.
Publicado: (2023)